Skip to main content

Table 6 Analysis of the prognostic factors

From: Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: results of a single-center long-term study

Factor N Single factor Multiple factors
RR 95% CI P RR 95% CI P
Age
  < 60 years 21 1    1   
  ≥ 60 years 6 1.58 0.957–2.164 0.086 1.97 1.180–2.668 0.059
Menstrual status
 Premenopausal 9       
 Postmenopausal 18 1.792 1.057–2.601 0.034 1.32 0.847–1.809 0.072
Primary tumor size (cm)
  < 2 15 1    1   
 2–5 6 1.675 1.011–2.917 0.045 1.115 0.980–3.028 0.021
  ≥ 5 5 2.174 1.039–4.632 0.037 2.538 1.157–4.251 0.001
 Tumor involving chest wall 1 3.548 1.387–8.171 0.040 1.478 1.245–1.773 0.004
Number of axillary metastatic lymph nodes
 0 14 1    1   
 1–3 8 1.726 0.962–2.928 0.049 1.971 1.939–3.752 0.041
  ≥ 4 5 2.279 1.062–3.373 0.001 1.960 1.017–3.758 0.037
ER/PR status
 Positive 18 1    1   
 Negative 9 2.120 1.204–3.243 0.024 2.310 1.673–3.554 0.000
Her-2 status
 Positive 15 1    1   
 Negative 12 1.490 1.245–1.783 0.01 1.971 1.193–3.255 0.150
Time to postoperative liver metastasis (months)   1    1   
 24 16       
  ≥ 24 11 1.971 1.073–3.578 0.028 0.561 0.327–0.965 0.037
Number of intrahepatic lesions (N)
 Single 5 1    1   
 Multiple 22 1.630 1.074–3.383 0.056 1.67 1.243–2.255 0.079
Size of intrahepatic lesions (cm)
  < 3 3 1    1   
  ≥ 3 24 1.524 0.448–2.171 0.012 1.822 1.028–3.339 0.060
Presence of extrahepatic metastasis
 Yes 16 1    1   
 No 11 1.578 1.012–3.654 0.001 0.258 0.214–1.012 0.593
Was combination therapy adopted?
 Yes 18 1    1   
 No 9 2.275 1.462–3.540 0.000 0.891 0.799–0.993 0.037